2. Summary of included studies.
| Trial ID | Country |
Randomized (N) |
Male (N; %) | Age (median; IQR or mean; SD) | Duration of antifungal therapy prior to randomization | Antifungal regimen | Time to ART initiation after randomization | ART regimen1 | Dropouts (N) | |
| Early | Delayed | |||||||||
| Bisson 2013 | Botswana | 28 | 14; 50 | 35 (32 to 41) | 72 hrs | Amphotericin B and fluconazole | 7 days (range 5 to 10) | 32 days (range 28 to 36) | TDF/FTC/EFV or NVP | 1 |
| Boulware 2014 | Uganda, South Africa | 177 | 93; 53 | 35 (28 to 40) early; 36 (30 to 40) delayed |
7 to 11 days | Amphotericin B and fluconazole | 1 to 2 weeks after diagnosis | 5 weeks after diagnosis | AZT/3TC/ EFV (80%), D4T/3TC/EFV (19%), TDF/3TC/EFV (1%) |
0 |
| Makadzange 2010 | Zimbabwe | 54 | 28; 52 | 37 (SD 8.5) early; 38 (SD 6.9) delayed |
0 days | Fluconazole | 72 hours | 10 weeks | D4T/3TC/ NVP | 6 |
| Zolopa 20092 | USA, Puerto Rico, South Africa | 35 | NR | NR | ≤ 14 days | NR | 48 hours | 6 to 12 weeks | NNRTI or PI + 2 NRTIs (3TC or FTC) | NR |
Abbreviations: IQR: interquartile range; N: number of participants; NR: not reported; SD: standard deviation; AZT: Zidovudine; D4T: Stavudine
1TDF: tenofovir; FTC: emtricitabine; EFV: efavirenz; NVP: nevirapine; 3TC: lamivudine; NNRTI: non‐nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor. 2This trial reported results for participants with a variety of opportunistic infections and did not provide descriptive data specifically for those with cryptococcal meningitis.